CARA Cara Therapeutics Inc

Cara Therapeutics Inc is an emerging biotechnology company. It is focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors.

$29.16  +1.69 (6.13%)
As of 04/09/2021 15:59:32 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  01/31/2014
Outstanding shares:  49,876,763
Average volume:  1,605,468
Market cap:   $1,455,902,712
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    140755109
ISIN:        US1407551092
Sedol:      BJ4YJ92
Valuation   (See tab for details)
PE ratio:   173.12
PB ratio:   5.85
PS ratio:   10.78
Return on equity:   3.38%
Net income %:   6.23%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy